약물감시 시장 점유율, 규모, 동향, 산업 분석 리포트 : 서비스별, 제품수명주기별, 유형별, 프로세스 플로우별, 치료 영역별, 최종 용도별, 지역별 부문별 예측(2024-2032년)

Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032

US $ 4,250 ￦ 5,986,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,250 ￦ 7,394,000

PDF (Multi User License)

PDF 보고서를 동일 기업 20명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,250 ￦ 8,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

Polaris Market Research의 최신 조사에 따르면 세계의 약물감시 시장 규모는 2032년까지 137억 5,000만 달러에 달할 전망입니다. 이 조사 리포트는 현재 시장 역학의 상세 인사이트와 향후 시장 성장에 관한 분석을 제공하고 있습니다.

시장의 주요 촉진요인으로는 약물 섭취량 증가, 신약 개발 빈도 증가, 약물 반응 음성 및 약물 독성 가격 상승, 약물감시 솔루션의 계약 추세 확대 등이 업계 성장을 가속할 것으로 예상됩니다. 또한 제약 부문의 과도한 지출, 약물 부작용 발생률 증가, 약물 오류로 인해 업계가 발전하고 있습니다. 또한 코로나바이러스 전염병은 백신에 대한 긴급한 수요를 창출하여 업계 참가자들에게 몇 가지 기회를 제공합니다.

고정적인 공급 비용을 변동 비용으로 전환하고, 주문형 전문 지식에 대한 온디맨드 접근성 등의 장점으로 인해 예측 기간 중 아웃소싱 계약 부문이 세계 시장에서 주요 점유율을 차지할 것으로 예상됩니다.

북미는 신약 도입에 대한 업계 기업의 투자 증가로 인해 예측 기간 중 세계 시장에서 주요 점유율을 차지할 것으로 예상됩니다. 또한 미국과 캐나다와 같은 국가에서는 첨단화된 의료 시스템의 존재와 함께 엄격한 규제가 업계 성장에 유리한 기회를 창출할 것으로 예상됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 약물감시 시장 인사이트

• 약물감시 - 업계 스냅숏
• 약물감시 시장 역학
  • 촉진요인과 기회
    • 만성질환의 만연
    • 의약품 개발에 대한 투자 증가
  • 억제요인과 과제
    • 데이터 관리에 관한 문제
• PESTLE 분석
• 약물감시 업계의 동향
• COVID-19의 영향 분석

제5장 세계의 약물감시 시장 : 서비스 프로바이더별

• 주요 조사 결과
• 서론
• 사내
• 계약 아웃소싱

제6장 세계의 약물감시 시장 : 제품수명주기별

• 주요 조사 결과
• 서론
• 전임상
• 단계 I
• 단계 II
• 단계 III
• 단계 IV

제7장 세계의 약물감시 시장 : 치료 영역별

• 주요 조사 결과
• 서론
• 종양학
• 신경학
• 심장병학
• 호흡기
• 기타

제8장 세계의 약물감시 시장 : 프로세스 플로우별

• 주요 조사 결과
• 서론
• 케이스 데이터 관리
• 신호 탐지
• 리스크 관리 시스템

제9장 세계의 약물감시 시장 : 유형별

• 주요 조사 결과
• 서론
• 자발적 보고
• ADR 보고 강화
• 표적 자발적 보고
• 코호트 이벤트 모니터링
• EHR 마이닝

제10장 세계의 약물감시 시장 : 최종 용도별

• 주요 조사 결과
• 서론
• 의약품
• 바이오테크놀러지 기업
• 의료기기 제조업체
• 기타

제11장 세계의 약물감시 시장 : 지역

• 주요 조사 결과
• 서론
  • 약물감시 시장의 평가 : 지역별, 2019-2032년
• 북미
  • 북미 : 서비스 프로바이더별, 2019-2032년
  • 북미 : 프로세스 플로우별, 2019-2032년
  • 북미 : 제품수명주기별, 2019-2032년
  • 북미 : 유형별, 2019-2032년
  • 북미 : 치료 영역별, 2019-2032년
  • 북미 : 최종 용도별, 2019-2032년
  • 미국
  • 캐나다
• 유럽
  • 유럽 : 서비스 프로바이더별, 2019-2032년
  • 유럽 : 프로세스 플로우별, 2019-2032년
  • 유럽 : 제품수명주기별, 2019-2032
  • 유럽 : 유형별, 2019-2032
  • 유럽 : 치료 영역별, 2019-2032년
  • 유럽 : 최종 용도별, 2019-2032년
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 네덜란드
  • 러시아
• 아시아태평양
  • 아시아태평양 : 서비스 프로바이더별, 2019-2032년
  • 아시아태평양 : 프로세스 플로우별, 2019-2032년
  • 아시아태평양 : 제품수명주기별, 2019-2032년
  • 아시아태평양 : 유형별, 2019-2032
  • 아시아태평양 : 치료 영역별, 2019-2032년
  • 아시아태평양 : 최종 용도별, 2019-2032년
  • 중국
  • 인도
  • 일본
  • 말레이시아
  • 인도네시아
  • 한국
• 중동 및 아프리카
  • 중동 및 아프리카 : 서비스 프로바이더별, 2019-2032년
  • 중동 및 아프리카 : 프로세스 플로우별, 2019-2032년
  • 중동 및 아프리카 : 제품수명주기별, 2019-2032
  • 중동 및 아프리카 : 유형별, 2019-2032년
  • 중동 및 아프리카 : 치료 영역별, 2019-2032년
  • 중동 및 아프리카 : 최종 용도별, 2019-2032년
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 남아프리카공화국
• 라틴아메리카
  • 라틴아메리카 : 서비스 프로바이더별, 2019-2032년
  • 라틴아메리카 : 프로세스 플로우별, 2019-2032년
  • 라틴아메리카 : 제품수명주기별, 2019-2032년
  • 라틴아메리카 : 유형별, 2019-2032년
  • 라틴아메리카 : 치료 영역별, 2019-2032년
  • 라틴아메리카 : 최종 용도별, 2019-2032년
  • 멕시코
  • 브라질
  • 아르헨티나

제12장 경쟁 구도

• 확대와 인수 분석
  • 확대
  • 인수
• 제휴/협업/합의/공개

제13장 기업 개요

• Accenture
• ArisGlobal
• BioClinica, Inc
• Capgemini
• Clinquest Group B.V.(Linical Americas)
• Cognizant
• FMD K&L
• IBM Corporation
• ICON Plc.
• IQVIA
• ITClinical
• Laboratory Corporation of America Holdings
• Linical Accelovance
• PAREXEL International Corporation
• TAKE Solutions
• United BioSource Corporation
• Wipro Limited

KSA

영문 목차

영문목차

The global pharmacovigilance market size is expected to reach USD 13.75 Billion by 2032 according to a new study by Polaris Market Research. The report "Pharmacovigilance Market Share, Size, Trends, Industry Analysis Report, By Service, By Product Life Cycle, By Type, By Process Flow, By Therapeutic Area, By End-Use, By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The primary drivers of the market include rising medication intake novel drug development frequencies, rising prices of negative drug responses and drug toxicities, as well as an expanding tendency of contracting pharmacovigilance solutions is expected to boost the industry growth. Moreover, the pharmaceutical sector's excessive expenditure, rising incidence of adverse drug events, and drug mistakes are propelling the industry forward. Furthermore, the coronavirus pandemic has produced an emergency demand for a vaccine that has offered several chances for industry participants.

The contract outsources segment is expected to hold the major shares in the global market during the forecast period due to its benefits such as transforming fixed supply costs into variables, refining on-demand contact to distinctive expertise along with other benefits.

North America is expected to hold the major share in the global market over the forecast period due to increasing investment by the industry players in introducing novel drugs. Moreover, stringent regulations along with the presence of advanced healthcare systems in countries like the U.S. and Canada are expected to create lucrative opportunities for industry growth.

Some of the major players operating in the global market are ArisGlobal, Accenture, BioClinica, Inc., United BioSource Corporation, Clinquest Group B.V. (Linical Americas), Cognizant, Capgemini, FMD K&L, IBM Corporation, IQVIA, ICON Plc., ITClinical, Linical Accelovance, PAREXEL International Corporation, Laboratory Corporation of America Holdings, TAKE Solutions, and Wipro Limited.

Polaris Market Research has segmented the pharmacovigilance market report on the basis of service provider, product life cycle, type, process flow, therapeutic area, end-use, and region:

Pharmacovigilance, Service Provider Outlook (Revenue - USD Billion, 2019-2032)

• In-house
• Contract Outsourcing

Pharmacovigilance, Product Life Cycle Outlook (Revenue - USD Billion, 2019-2032)

• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Pharmacovigilance, Type Outlook (Revenue - USD Billion, 2019-2032)

• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Pharmacovigilance, Process Flow Outlook (Revenue - USD Billion, 2019-2032)

• Case Data Management
• Case Logging
• Case Data Analysis
• Medical Reviewing & Reporting
• Signal Detection
• Adverse Event Logging
• Adverse Event Analysis
• Adverse Event Review & Reporting
• Risk Management System
• Risk Evaluation System
• Risk Mitigation System

Pharmacovigilance, Therapeutic Area Outlook (Revenue - USD Billion, 2019-2032)

• Oncology
• Neurology
• Cardiology
• Respiratory Systems
• Others

Pharmacovigilance, End-Use Outlook (Revenue - USD Billion, 2019-2032)

• Pharmaceuticals
• Biotechnology Companies
• Medical Device Manufacturers
• Others

Pharmacovigilance, Regional Outlook (Revenue - USD Billion, 2019-2032)

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• Italy
• France
• Netherlands
• Russia
• Spain
• Asia Pacific
• China
• Japan
• India
• Indonesia
• Malaysia
• South Korea
• Latin America
• Brazil
• Argentina
• Mexico
• Middle East & Africa
• Israel
• Saudi Arabia
• South Africa
• UAE

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Pharmacovigilance Market Insights

• 4.1. Pharmacovigilance - Industry Snapshot
• 4.2. Pharmacovigilance Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rising prevalence of chronic disease
    • 4.2.1.2. Increasing investment in drug development
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. Issues related to data management
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Pharmacovigilance Industry Trends
• 4.6. COVID-19 Impact Analysis

5. Global Pharmacovigilance Market, by Service Provider

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
• 5.3. In-house
  • 5.3.1. Global Pharmacovigilance Market, by In-house, by Region, 2019-2032 (USD Billion)
• 5.4. Contract Outsourcing
  • 5.4.1. Global Pharmacovigilance Market, by Contract Outsourcing, by Region, 2019-2032 (USD Billion)

6. Global Pharmacovigilance Market, by Product Life Cycle

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
• 6.3. Pre-clinical
  • 6.3.1. Global Pharmacovigilance Market, by Pre-clinical, by Region, 2019-2032 (USD Billion)
• 6.4. Phase I
  • 6.4.1. Global Pharmacovigilance Market, by Phase I, by Region, 2019-2032 (USD Billion)
• 6.5. Phase II
  • 6.5.1. Global Pharmacovigilance Market, by Phase II, by Region, 2019-2032 (USD Billion)
• 6.6. Phase III
  • 6.6.1. Global Pharmacovigilance Market, by Phase III, by Region, 2019-2032 (USD Billion)
• 6.7. Phase IV
  • 6.7.1. Global Pharmacovigilance Market, by Phase IV, by Region, 2019-2032 (USD Billion)

7. Global Pharmacovigilance Market, by Therapeutic Area

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
• 7.3. Oncology
  • 7.3.1. Global Pharmacovigilance Market, by Oncology, by Region, 2019-2032 (USD Billion)
• 7.4. Neurology
  • 7.4.1. Global Pharmacovigilance Market, by Neurology, by Region, 2019-2032 (USD Billion)
• 7.5. Cardiology
  • 7.5.1. Global Pharmacovigilance Market, by Cardiology, by Region, 2019-2032 (USD Billion)
• 7.6. Respiratory Systems
  • 7.6.1. Global Pharmacovigilance Market, by Respiratory Systems, by Region, 2019-2032 (USD Billion)
• 7.7. Others
  • 7.7.1. Global Other Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

8. Global Pharmacovigilance Market, by Process Flow

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
• 8.3. Case Data Management
  • 8.3.1. Global Pharmacovigilance Market, by Case Data Management, by Region, 2019-2032 (USD Billion)
  • 8.3.2. Case Logging
    • 8.3.2.1. Global Pharmacovigilance Market, by Case Logging, by Region, 2019-2032 (USD Billion)
  • 8.3.3. Case Data Analysis
    • 8.3.3.1. Global Pharmacovigilance Market, by Case Data Analysis, by Region, 2019-2032 (USD Billion)
  • 8.3.4. Medical Reviewing & Reporting
    • 8.3.4.1. Global Pharmacovigilance Market, by Medical Reviewing & Reporting, by Region, 2019-2032 (USD Billion)
• 8.4. Signal Detection
  • 8.4.1. Global Pharmacovigilance Market, by Signal Detection, by Region, 2019-2032 (USD Billion)
  • 8.4.2. Adverse Event Logging
    • 8.4.2.1. Global Pharmacovigilance Market, by Adverse Event Logging, by Region, 2019-2032 (USD Billion)
  • 8.4.3. Adverse Event Analysis
    • 8.4.3.1. Global Pharmacovigilance Market, by Adverse Event Analysis, by Region, 2019-2032 (USD Billion)
  • 8.4.4. Adverse Event Review & Reporting
    • 8.4.4.1. Global Pharmacovigilance Market, by Adverse Event Review & Reporting, by Region, 2019-2032 (USD Billion)
• 8.5. Risk Management System
  • 8.5.1. Global Pharmacovigilance Market, by Risk Management System, by Region, 2019-2032 (USD Billion)
  • 8.5.2. Risk Evaluation System
    • 8.5.2.1. Global Pharmacovigilance Market, by Risk Evaluation System, by Region, 2019-2032 (USD Billion)
  • 8.5.3. Risk Mitigation System
    • 8.5.3.1. Global Pharmacovigilance Market, by Risk Mitigation System, by Region, 2019-2032 (USD Billion)

9. Global Pharmacovigilance Market, by Type

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Global Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
• 9.3. Spontaneous Reporting
  • 9.3.1. Global Pharmacovigilance Market, by Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
• 9.4. Intensified ADR Reporting
  • 9.4.1. Global Pharmacovigilance Market, by Intensified ADR Reporting, by Region, 2019-2032 (USD Billion)
• 9.5. Targeted Spontaneous Reporting
  • 9.5.1. Global Pharmacovigilance Market, by Targeted Spontaneous Reporting, by Region, 2019-2032 (USD Billion)
• 9.6. Cohort Event Monitoring
  • 9.6.1. Global Pharmacovigilance Market, by Cohort Event Monitoring, by Region, 2019-2032 (USD Billion)
• 9.7. EHR Mining
  • 9.7.1. Global Pharmacovigilance Market, by EHR Mining, by Region, 2019-2032 (USD Billion)

10. Global Pharmacovigilance Market, by End-Use

• 10.1. Key Findings
• 10.2. Introduction
  • 10.2.1. Global Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
• 10.3. Pharmaceuticals
  • 10.3.1. Global Pharmacovigilance Market, by Pharmaceuticals, by Region, 2019-2032 (USD Billion)
• 10.4. Biotechnology Companies
  • 10.4.1. Global Pharmacovigilance Market, by Biotechnology Companies, by Region, 2019-2032 (USD Billion)
• 10.5. Medical Device Manufacturers
  • 10.5.1. Global Pharmacovigilance Market, by Medical Device Manufacturers, by Region, 2019-2032 (USD Billion)
• 10.6. Others
  • 10.6.1. Global Other End-Uses Pharmacovigilance Market, by Region, 2019-2032 (USD Billion)

11. Global Pharmacovigilance Market, by Geography

• 11.1. Key findings
• 11.2. Introduction
  • 11.2.1. Pharmacovigilance Market Assessment, By Geography, 2019-2032 (USD Billion)
• 11.3. Pharmacovigilance Market - North America
  • 11.3.1. North America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 11.3.2. North America: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 11.3.3. North America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 11.3.4. North America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 11.3.5. North America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 11.3.6. North America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.3.7. Pharmacovigilance Market - U.S.
    • 11.3.7.1. U.S.: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.3.7.2. U.S.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.3.7.3. U.S.: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.3.7.4. U.S.: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.3.7.5. U.S.: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.3.7.6. U.S.: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.3.8. Pharmacovigilance Market - Canada
    • 11.3.8.1. Canada: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.3.8.2. Canada.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.3.8.3. Canada: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.3.8.4. Canada: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.3.8.5. Canada: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.3.8.6. Canada: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
• 11.4. Pharmacovigilance Market - Europe
  • 11.4.1. Europe: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 11.4.2. Europe.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 11.4.3. Europe: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 11.4.4. Europe: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 11.4.5. Europe: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 11.4.6. Europe: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4.7. Pharmacovigilance Market - UK
    • 11.4.7.1. UK: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.7.2. UK.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.7.3. UK: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.7.4. UK: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.7.5. UK: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.7.6. UK: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4.8. Pharmacovigilance Market - France
    • 11.4.8.1. France: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.8.2. France.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.8.3. France: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.8.4. France: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.8.5. France: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.8.6. France: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4.9. Pharmacovigilance Market - Germany
    • 11.4.9.1. Germany: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.9.2. Germany.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.9.3. Germany: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.9.4. Germany: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.9.5. Germany: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.9.6. Germany: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4.10. Pharmacovigilance Market - Italy
    • 11.4.10.1. Italy: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.10.2. Italy.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.10.3. Italy: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.10.4. Italy: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.10.5. Italy: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.10.6. Italy: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4.11. Pharmacovigilance Market - Spain
    • 11.4.11.1. Spain: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.11.2. Spain.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.11.3. Spain: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.11.4. Spain: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.11.5. Spain: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.11.6. Spain: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4.12. Pharmacovigilance Market - Netherlands
    • 11.4.12.1. Netherlands: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.12.2. Netherlands.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.12.3. Netherlands: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.12.4. Netherlands: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.12.5. Netherlands: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.12.6. Netherlands: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.4.13. Pharmacovigilance Market - Russia
    • 11.4.13.1. Russia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.4.13.2. Russia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.4.13.3. Russia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.4.13.4. Russia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.4.13.5. Russia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.4.13.6. Russia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
• 11.5. Pharmacovigilance Market - Asia Pacific
  • 11.5.1. Asia Pacific: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 11.5.2. Asia Pacific.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 11.5.3. Asia Pacific: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 11.5.4. Asia Pacific: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 11.5.5. Asia Pacific: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 11.5.6. Asia Pacific: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5.7. Pharmacovigilance Market - China
    • 11.5.7.1. China: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.7.2. China.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.7.3. China: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.7.4. China: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.7.5. China: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.7.6. China: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5.8. Pharmacovigilance Market - India
    • 11.5.8.1. India: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.8.2. India.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.8.3. India: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.8.4. India: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.8.5. India: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.8.6. India: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5.9. Pharmacovigilance Market - Japan
    • 11.5.9.1. Japan: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.9.2. Japan.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.9.3. Japan: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.9.4. Japan: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.9.5. Japan: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.9.6. Japan: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5.10. Pharmacovigilance Market - Malaysia
    • 11.5.10.1. Malaysia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.10.2. Malaysia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.10.3. Malaysia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.10.4. Malaysia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.10.5. Malaysia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.10.6. Malaysia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5.11. Pharmacovigilance Market - Indonesia
    • 11.5.11.1. Indonesia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.11.2. Indonesia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.11.3. Indonesia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.11.4. Indonesia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.11.5. Indonesia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.11.6. Indonesia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.5.12. Pharmacovigilance Market - South Korea
    • 11.5.12.1. South Korea: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.5.12.2. South Korea.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.5.12.3. South Korea: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.5.12.4. South Korea: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.5.12.5. South Korea: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.5.12.6. South Korea: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
• 11.6. Pharmacovigilance Market - Middle East & Africa
  • 11.6.1. Middle East & Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 11.6.2. Middle East & Africa: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 11.6.3. Middle East & Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 11.6.4. Middle East & Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 11.6.5. Middle East & Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 11.6.6. Middle East & Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6.7. Pharmacovigilance Market - Saudi Arabia
    • 11.6.7.1. Saudi Arabia: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.7.2. Saudi Arabia.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.7.3. Saudi Arabia: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.7.4. Saudi Arabia: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.7.5. Saudi Arabia: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.7.6. Saudi Arabia: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6.8. Pharmacovigilance Market - UAE
    • 11.6.8.1. UAE: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.8.2. UAE.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.8.3. UAE: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.8.4. UAE: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.8.5. UAE: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.8.6. UAE: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6.9. Pharmacovigilance Market - Israel
    • 11.6.9.1. Israel: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.9.2. Israel.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.9.3. Israel: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.9.4. Israel: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.9.5. Israel: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.9.6. Israel: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.6.10. Pharmacovigilance Market - South Africa
    • 11.6.10.1. South Africa: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.6.10.2. South Africa.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.6.10.3. South Africa: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.6.10.4. South Africa: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.6.10.5. South Africa: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.6.10.6. South Africa: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
• 11.7. Pharmacovigilance Market - Latin America
  • 11.7.1. Latin America: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
  • 11.7.2. Latin America.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
  • 11.7.3. Latin America: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
  • 11.7.4. Latin America: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
  • 11.7.5. Latin America: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
  • 11.7.6. Latin America: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.7.7. Pharmacovigilance Market - Mexico
    • 11.7.7.1. Mexico: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.7.7.2. Mexico.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.7.7.3. Mexico: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.7.7.4. Mexico: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.7.7.5. Mexico: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.7.7.6. Mexico: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.7.8. Pharmacovigilance Market - Brazil
    • 11.7.8.1. Brazil: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.7.8.2. Brazil.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.7.8.3. Brazil: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.7.8.4. Brazil: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.7.8.5. Brazil: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.7.8.6. Brazil: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)
  • 11.7.9. Pharmacovigilance Market - Argentina
    • 11.7.9.1. Argentina: Pharmacovigilance Market, by Service Provider, 2019-2032 (USD Billion)
    • 11.7.9.2. Argentina.: Pharmacovigilance Market, by Process Flow, 2019-2032 (USD Billion)
    • 11.7.9.3. Argentina: Pharmacovigilance Market, by Product Life Cycle, 2019-2032 (USD Billion)
    • 11.7.9.4. Argentina: Pharmacovigilance Market, by Type, 2019-2032 (USD Billion)
    • 11.7.9.5. Argentina: Pharmacovigilance Market, by Therapeutic Area, 2019-2032 (USD Billion)
    • 11.7.9.6. Argentina: Pharmacovigilance Market, by End-Use, 2019-2032 (USD Billion)

12. Competitive Landscape

• 12.1. Expansion and Acquisition Analysis
  • 12.1.1. Expansion
  • 12.1.2. Acquisitions
• 12.2. Partnerships/Collaborations/Agreements/Exhibitions

13. Company Profiles

• 13.1. Accenture
  • 13.1.1. Company Overview
  • 13.1.2. Financial Performance
  • 13.1.3. Product Benchmarking
  • 13.1.4. Recent Development
• 13.2. ArisGlobal
  • 13.2.1. Company Overview
  • 13.2.2. Financial Performance
  • 13.2.3. Product Benchmarking
  • 13.2.4. Recent Development
• 13.3. BioClinica, Inc
  • 13.3.1. Company Overview
  • 13.3.2. Financial Performance
  • 13.3.3. Product Benchmarking
  • 13.3.4. Recent Development
• 13.4. Capgemini
  • 13.4.1. Company Overview
  • 13.4.2. Financial Performance
  • 13.4.3. Product Benchmarking
  • 13.4.4. Recent Development
• 13.5. Clinquest Group B.V. (Linical Americas)
  • 13.5.1. Company Overview
  • 13.5.2. Financial Performance
  • 13.5.3. Product Benchmarking
  • 13.5.4. Recent Development
• 13.6. Cognizant
  • 13.6.1. Company Overview
  • 13.6.2. Financial Performance
  • 13.6.3. Product Benchmarking
  • 13.6.4. Recent Development
• 13.7. FMD K&L
  • 13.7.1. Company Overview
  • 13.7.2. Financial Performance
  • 13.7.3. Product Benchmarking
  • 13.7.4. Recent Development
• 13.8. IBM Corporation
  • 13.8.1. Company Overview
  • 13.8.2. Financial Performance
  • 13.8.3. Product Benchmarking
  • 13.8.4. Recent Development
• 13.9. ICON Plc.
  • 13.9.1. Company Overview
  • 13.9.2. Financial Performance
  • 13.9.3. Product Benchmarking
  • 13.9.4. Recent Development
• 13.10. IQVIA
  • 13.10.1. Company Overview
  • 13.10.2. Financial Performance
  • 13.10.3. Product Benchmarking
  • 13.10.4. Recent Development
• 13.11. ITClinical
  • 13.11.1. Company Overview
  • 13.11.2. Financial Performance
  • 13.11.3. Product Benchmarking
  • 13.11.4. Recent Development
• 13.12. Laboratory Corporation of America Holdings
  • 13.12.1. Company Overview
  • 13.12.2. Financial Performance
  • 13.12.3. Product Benchmarking
  • 13.12.4. Recent Development
• 13.13. Linical Accelovance
  • 13.13.1. Company Overview
  • 13.13.2. Financial Performance
  • 13.13.3. Product Benchmarking
  • 13.13.4. Recent Development
• 13.14. PAREXEL International Corporation
  • 13.14.1. Company Overview
  • 13.14.2. Financial Performance
  • 13.14.3. Product Benchmarking
  • 13.14.4. Recent Development
• 13.15. TAKE Solutions
  • 13.15.1. Company Overview
  • 13.15.2. Financial Performance
  • 13.15.3. Product Benchmarking
  • 13.15.4. Recent Development
• 13.16. United BioSource Corporation
  • 13.16.1. Company Overview
  • 13.16.2. Financial Performance
  • 13.16.3. Product Benchmarking
  • 13.16.4. Recent Development
• 13.17. Wipro Limited
  • 13.17.1. Company Overview
  • 13.17.2. Financial Performance
  • 13.17.3. Product Benchmarking
  • 13.17.4. Recent Development

관련자료